Overall, these findings denote the promises of AADvac1 immunotherapy against tau for alleviation or reversal of tau pathology and symptoms in AD patients; nonetheless, further clinical trials on a larger scale are warranted. This evidence concerns the gene MAPT and Alzheimer disease.